131719-55-6

Basic information

• Product Name: diethyl <4-(benzyloxy)benzyl>phosphonate
• Synonyms: diethyl <4-(benzyloxy)benzyl>phosphonate
• CAS NO: 131719-55-6
• Molecular Weight: 334.352
• Mol File: 131719-55-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 466.0±33.0 °C(Predicted)
• Density: 1.139±0.06 g/cm3(Predicted)
• CAS DataBase Reference: diethyl <4-(benzyloxy)benzyl>phosphonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl <4-(benzyloxy)benzyl>phosphonate(131719-55-6)
• EPA Substance Registry System: diethyl <4-(benzyloxy)benzyl>phosphonate(131719-55-6)

Safety Data

• Hazardous Substances Data: 131719-55-6(Hazardous Substances Data)

Upstream product

• 836-43-1 4-benzyloxybenzyl alcohol 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 836-42-0 4-benzyloxybenzyl chloride 
• 122-52-1 triethyl phosphite 
• 5544-60-5 4-(benzyloxy)benzyl bromide 

Downstream Products

• 3173-38-4 diethyl 4-(hydroxy)benzylphosphonate 
• 1875-21-4 bibenzyl-2,4'-diol 
• 63877-76-9 (E)-4-<2-(3-hydroxyphenyl)ethenyl>phenol 
• 501-36-0 (E)-5-[2-4-(hydroxyphenyl)ethenyl]-1,3-benzenediol 
• 14064-83-6 trans-4-hydroxy-4'-nitrostilbene 
• 24265-91-6 4-benzyloxy-4'-nitrostilbene 
• 1875-18-9 2,4'-Dibenzyloxy-stilben 
• 659-22-3 trans-4,4'-dihydroxystilbene 

Relevant articles and documents

Efficient synthesis of small-sized phosphonated dendrons: Potential organic coatings of iron oxide nanoparticles

We report herein the synthesis of biocompatible small-sized phosphonated monomers and dendrons used as functional coatings of metal oxide nanoparticles, more specifically superparamagnetic iron oxides (SPIOs) for magnetic resonance imaging (MRI) and therapy through hyperthermia. The molecules were engineered to modulate their size, their hydrophilic and/or biocompatible character (poly(amido)amine versus oligoethyleneglycol), the number of anchoring phosphonate groups (monophosphonate versus phosphonic tweezers) and the number of peripheral functional groups for further grafting of dyes or specific vectors. Such a library of hydrophilic phosphonic acids opens new possibilities for the investigation of dendronized nanohybrids as theranostics.

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.